Insulin Glargine Recombinant Patents

Given below is the list of patents protecting Insulin Glargine Recombinant, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Glargine Recombinant's patents.

Latest Legal Activities on Insulin Glargine Recombinant's Patents

Given below is the list recent legal activities going on the following patents of Insulin Glargine Recombinant.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 8th Year, Large Entity	08 Nov, 2023	US9345750
Payment of Maintenance Fee, 4th Year, Large Entity	25 Jan, 2023	US10369291
Post Issue Communication - Certificate of Correction	13 Nov, 2019	US10369291
Payment of Maintenance Fee, 4th Year, Large Entity	08 Nov, 2019	US9345750
Recordation of Patent Grant Mailed Critical	06 Aug, 2019	US10369291
Patent Issue Date Used in PTA Calculation Critical	06 Aug, 2019	US10369291
Email Notification Critical	18 Jul, 2019	US10369291
Issue Notification Mailed Critical	17 Jul, 2019	US10369291
Dispatch to FDC	26 Jun, 2019	US10369291
Application Is Considered Ready for Issue Critical	20 Jun, 2019	US10369291

Insulin Glargine Recombinant's Family Patents

Full family tree

Explore Our Curated Drug Screens